NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial
Clinical trial NCT06450041 · RECRUITING
Trial details
- NCT number
- NCT06450041
- Sponsor
- New Approaches to Neuroblastoma Therapy Consortium
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-12-16
- Primary completion
- 2028-12-01
- Enrollment
- 62
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.